Selected research
Industry Research
Idiopathic Pulmonary Fibrosis Disease Treatment Industry Research Report 2026
Market perspective
The global Idiopathic Pulmonary Fibrosis Disease Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Idiopathic Pulmonary Fibrosis Disease Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Idiopathic Pulmonary Fibrosis Disease Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Idiopathic Pulmonary Fibrosis Disease Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Idiopathic Pulmonary Fibrosis Disease Treatment include Blade Therapeutics, Bristol Myers Squibb, InterMune, Inc., Vicore Pharma, ArkBio, Boehringer Ingelheim, Regend Therapeutics (Cayman) Ltd., Merck and Co., Inc. and SHIONOGI & CO., Ltd., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Idiopathic Pulmonary Fibrosis Disease Treatment market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Idiopathic Pulmonary Fibrosis Disease Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Idiopathic Pulmonary Fibrosis Disease Treatment Market by Company
Blade Therapeutics
Bristol Myers Squibb
InterMune, Inc.
Vicore Pharma
ArkBio
Boehringer Ingelheim
Regend Therapeutics (Cayman) Ltd.
Merck and Co., Inc.
SHIONOGI & CO., Ltd.
Insilico Medicine
Indaco
Zelgen
Heilongjiang Zbd Pharmaceutical
Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Type
Pirfenidone
Nintedanib
Other
Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Application
Hospital
Graduate School
Others
Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Idiopathic Pulmonary Fibrosis Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Idiopathic Pulmonary Fibrosis Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Idiopathic Pulmonary Fibrosis Disease Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Idiopathic Pulmonary Fibrosis Disease Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pirfenidone
- Nintedanib
- Other
Applications
- Hospital
- Graduate School
- Others
Companies covered
- Blade Therapeutics
- Bristol Myers Squibb
- InterMune, Inc.
- Vicore Pharma
- ArkBio
- Boehringer Ingelheim
- Regend Therapeutics (Cayman) Ltd.
- Merck and Co., Inc.
- SHIONOGI & CO., Ltd.
- Insilico Medicine
- Indaco
- Zelgen
- Heilongjiang Zbd Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Idiopathic Pulmonary Fibrosis Disease Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Pirfenidone
- 2.2.3 Nintedanib
- 2.2.4 Other
- 2.3 Idiopathic Pulmonary Fibrosis Disease Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Graduate School
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Idiopathic Pulmonary Fibrosis Disease Treatment Breakdown Data by Type
- 3.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecasted Market Size by Type (2027-2032)
4 Idiopathic Pulmonary Fibrosis Disease Treatment Breakdown Data by Application
- 4.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Perspective (2021-2032)
- 5.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Growth Trends by Region
- 5.2.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Idiopathic Pulmonary Fibrosis Disease Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Idiopathic Pulmonary Fibrosis Disease Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Idiopathic Pulmonary Fibrosis Disease Treatment Market Dynamics
- 5.3.1 Idiopathic Pulmonary Fibrosis Disease Treatment Industry Trends
- 5.3.2 Idiopathic Pulmonary Fibrosis Disease Treatment Market Drivers
- 5.3.3 Idiopathic Pulmonary Fibrosis Disease Treatment Market Challenges
- 5.3.4 Idiopathic Pulmonary Fibrosis Disease Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Idiopathic Pulmonary Fibrosis Disease Treatment Players by Revenue
- 6.1.1 Global Top Idiopathic Pulmonary Fibrosis Disease Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Idiopathic Pulmonary Fibrosis Disease Treatment Head Office and Area Served
- 6.4 Global Idiopathic Pulmonary Fibrosis Disease Treatment Players, Product Type & Application
- 6.5 Global Idiopathic Pulmonary Fibrosis Disease Treatment Manufacturers Established Date
- 6.6 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2021-2032)
- 7.2 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026)
- 7.4 North America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2021-2032)
- 8.2 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026)
- 8.4 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2021-2032)
- 10.2 South America Idiopathic Pulmonary Fibrosis Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026)
- 10.4 South America Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Blade Therapeutics
- 12.1.1 Blade Therapeutics Company Information
- 12.1.2 Blade Therapeutics Business Overview
- 12.1.3 Blade Therapeutics Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2021-2026)
- 12.1.4 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
- 12.1.5 Blade Therapeutics Recent Developments
- 12.2 Bristol Myers Squibb
- 12.2.1 Bristol Myers Squibb Company Information
- 12.2.2 Bristol Myers Squibb Business Overview
- 12.2.3 Bristol Myers Squibb Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2021-2026)
- 12.2.4 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
- 12.2.5 Bristol Myers Squibb Recent Developments
- 12.3 InterMune, Inc.
- 12.3.1 InterMune, Inc. Company Information
- 12.3.2 InterMune, Inc. Business Overview
- 12.3.3 InterMune, Inc. Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2021-2026)
- 12.3.4 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
- 12.3.5 InterMune, Inc. Recent Developments
- 12.4 Vicore Pharma
- 12.4.1 Vicore Pharma Company Information
- 12.4.2 Vicore Pharma Business Overview
- 12.4.3 Vicore Pharma Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2021-2026)
- 12.4.4 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
- 12.4.5 Vicore Pharma Recent Developments
- 12.5 ArkBio
- 12.5.1 ArkBio Company Information
- 12.5.2 ArkBio Business Overview
- 12.5.3 ArkBio Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2021-2026)
- 12.5.4 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
- 12.5.5 ArkBio Recent Developments
- 12.6 Boehringer Ingelheim
- 12.6.1 Boehringer Ingelheim Company Information
- 12.6.2 Boehringer Ingelheim Business Overview
- 12.6.3 Boehringer Ingelheim Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2021-2026)
- 12.6.4 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
- 12.6.5 Boehringer Ingelheim Recent Developments
- 12.7 Regend Therapeutics (Cayman) Ltd.
- 12.7.1 Regend Therapeutics (Cayman) Ltd. Company Information
- 12.7.2 Regend Therapeutics (Cayman) Ltd. Business Overview
- 12.7.3 Regend Therapeutics (Cayman) Ltd. Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2021-2026)
- 12.7.4 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
- 12.7.5 Regend Therapeutics (Cayman) Ltd. Recent Developments
- 12.8 Merck and Co., Inc.
- 12.8.1 Merck and Co., Inc. Company Information
- 12.8.2 Merck and Co., Inc. Business Overview
- 12.8.3 Merck and Co., Inc. Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2021-2026)
- 12.8.4 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
- 12.8.5 Merck and Co., Inc. Recent Developments
- 12.9 SHIONOGI & CO., Ltd.
- 12.9.1 SHIONOGI & CO., Ltd. Company Information
- 12.9.2 SHIONOGI & CO., Ltd. Business Overview
- 12.9.3 SHIONOGI & CO., Ltd. Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2021-2026)
- 12.9.4 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
- 12.9.5 SHIONOGI & CO., Ltd. Recent Developments
- 12.10 Insilico Medicine
- 12.10.1 Insilico Medicine Company Information
- 12.10.2 Insilico Medicine Business Overview
- 12.10.3 Insilico Medicine Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2021-2026)
- 12.10.4 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
- 12.10.5 Insilico Medicine Recent Developments
- 12.11 Indaco
- 12.11.1 Indaco Company Information
- 12.11.2 Indaco Business Overview
- 12.11.3 Indaco Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2021-2026)
- 12.11.4 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
- 12.11.5 Indaco Recent Developments
- 12.12 Zelgen
- 12.12.1 Zelgen Company Information
- 12.12.2 Zelgen Business Overview
- 12.12.3 Zelgen Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2021-2026)
- 12.12.4 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
- 12.12.5 Zelgen Recent Developments
- 12.13 Heilongjiang Zbd Pharmaceutical
- 12.13.1 Heilongjiang Zbd Pharmaceutical Company Information
- 12.13.2 Heilongjiang Zbd Pharmaceutical Business Overview
- 12.13.3 Heilongjiang Zbd Pharmaceutical Revenue in Idiopathic Pulmonary Fibrosis Disease Treatment Business (2021-2026)
- 12.13.4 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Product Portfolio
- 12.13.5 Heilongjiang Zbd Pharmaceutical Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst